


# Kidney Cancer Drugs Market Manufacturers Develop Biomarkers To Predict The Drug Efficacy

*The Business Research Company's Kidney Cancer Drugs Market 2022 – Opportunities And Strategies – Global Forecast To 2030*

LONDON, GREATER LONDON, UK, June 24, 2022 /EINPresswire.com/ --

Manufacturers are increasingly using biomarkers in the drug development process to help reduce the time taken to bring the product into the market which is one of the key kidney cancer drugs market trends. Biomarkers are biological indicators that help objectively measure and evaluate biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention. They are also helpful in predicting the drug efficacy faster than conventional clinical endpoints, the point at which an undesired or abnormal effect of the drug is observed indicating withdrawal from therapy. Entities in this market are increasingly investing in the development of biomarkers for use in various activities such as studying pharmacodynamics (relationship between the drug concentration at the site of action and the biochemical and physiological effect) of drugs, tracking drug activity, and studying diseases and treatment pathways.



Entities in this market are increasingly investing in the development of biomarkers for use in various activities such as studying pharmacodynamics (relationship between the drug concentration at the site of action and the biochemical and physiological effect) of drugs, tracking drug activity, and studying diseases and treatment pathways.

Read more on the Global Kidney Cancer Drugs Market Report

<https://www.thebusinessresearchcompany.com/report/kidney-cancer-drugs-market>

The [global kidney cancer drugs market size](#) is expected to grow from \$3.60 billion in 2020 to \$4.52 billion in 2025 at a compound annual growth rate of 4.6%. The global kidney cancer drugs market size is then expected to grow at a CAGR of 2.1% from 2025 and reach \$5.02 billion in 2030.

The increasing aging population is expected to drive the prevalence of kidney cancer cases contributing to the kidney cancer drugs industry growth. The elderly population is increasing rapidly across the world and it is expected to continue over the forecast period. According to National Center for Biotechnology Information, about 60% of cancer cases occurs in people with

65 years or older and 75% of deaths caused by cancer in this stage. Thereby, it is considered that kidney cancer is a disease of old age. The expected increase in the aging population suffering from kidney cancer is expected to drive the kidney cancer drugs market.

Major players covered in the global kidney cancer drugs industry are Pfizer Inc., Novartis AG, Exelixis, Inc., F. Hoffmann-La Roche AG, Bristol Myers Squibb Company.

TBRC's kidney cancer drugs market segmentation is divided by type into renal cell carcinoma (RCC), transitional cell carcinoma (TCC) or urothelial cell carcinoma (UCC), by product into nexavar (sorafenib), sutent (sunitinib), afinitor (everolimus), votrient (pazopanib), avastin (bevacizumab), inlyta (axitinib), other products, by end user into hospitals, clinics, research center, others.

[Kidney Cancer Drugs Market 2022](#) – By Type (Renal Cell Carcinoma (RCC), Transitional Cell Carcinoma (TCC) Or Urothelial Cell Carcinoma (UCC)), By Product (Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib)), By End Users (Hospitals, Clinics, Research Center), And By Region, Opportunities And Strategies – Global Forecast To 2030 is one of a series of new reports from The Business Research Company that provides a kidney cancer drugs market overview, forecast kidney cancer drugs market size and growth for the whole market, kidney cancer drugs market segments, geographies, kidney cancer drugs market trends, kidney cancer drugs market drivers, restraints, leading competitors' revenues, profiles, and market shares.

Request for a Sample of the Global Kidney Cancer Drugs Market Report

<https://www.thebusinessresearchcompany.com/sample.aspx?id=6234&type=smp>

Not what you were looking for? Here is a list of similar reports by The Business Research Company:

Cancer Monoclonal Antibodies Global Market Report 2022 – By Monoclonal Antibody Therapies (Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbix), Panitumumab (Vectibix)), By Application (Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer), By End User (Hospitals And Clinics, Research Laboratories, Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/cancer-monoclonal-antibodie-global-market-report>

Cancer Clinical Decision Tools Global Market Report 2022 – By Type (Risk Assessment Tool (RAT), Qcancer), By End-User (Hospital, Clinics) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/cancer-clinical-decision-tool-global-market-report>

Cancer Biologics Global Market Report 2022 – By Type (Monoclonal Antibodies, Vaccines, Cell And Gene Therapy), By Application (Non-Small Cell Lung Cancer, Prostate Cancer, Breast Cancer,

Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers), By Distribution Channel (Hospitals, Clinics) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report>

### [About The Business Research Company](#)

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Read more about us at <https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx>

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

The Business Research Company

Email: [info@tbrc.info](mailto:info@tbrc.info)

Follow us on LinkedIn: <https://bit.ly/3b7850r>

Follow us on Twitter: <https://bit.ly/3b1rmjS>

Check out our Blog: <http://blog.tbrc.info/>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

[info@tbrc.info](mailto:info@tbrc.info)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/578266348>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.